Quest Diagnostics Receivables 2010-2024 | DGX

Quest Diagnostics receivables for the quarter ending June 30, 2024 were $1.319B, a 6.8% increase year-over-year.

  • Quest Diagnostics receivables for 2023 were $1.21B, a 1.26% increase from 2022.
  • Quest Diagnostics receivables for 2022 were $1.195B, a 16.9% decline from 2021.
  • Quest Diagnostics receivables for 2021 were $1.438B, a 5.39% decline from 2020.

Quest Diagnostics Receivables 2010-2024 | DGX

  • Quest Diagnostics receivables for 2023 were $1.21B, a 1.26% increase from 2022.
  • Quest Diagnostics receivables for 2022 were $1.195B, a 16.9% decline from 2021.
  • Quest Diagnostics receivables for 2021 were $1.438B, a 5.39% decline from 2020.
Related Stocks
Company NameMarket
Cap
Fresenius SE (FSNUY)$21.4B
DaVita (DVA)$13.7B
Encompass Health (EHC)$9.3B
Chemed (CHE)$8.7B
Elanco Animal Health (ELAN)$7.2B
Option Care Health (OPCH)$5.3B
RadNet (RDNT)$5B
Amedisys (AMED)$3.2B
Astrana Health (ASTH)$2.8B
LifeStance Health (LFST)$2.6B
Addus HomeCare (ADUS)$2.4B
U.S Physical Therapy (USPH)$1.3B
Pennant (PNTG)$1.1B
Aveanna Healthcare Holdings (AVAH)$1B
Atai Life Sciences (ATAI)$208M
Daxor (DXR)$45M
ATI Physical Therapy (ATIP)$25M
MEDIROM Healthcare Technologies (MRM)$19M
Psychemedics (PMD)$14M
Ontrak (OTRK)$10M
Novo Integrated Sciences (NVOS)$6M
IMAC Holdings (BACK)$2M